Hypercoagulability test strategies in the protein C and protein S pathway

Clinics in Laboratory Medicine

Volumn 22, Issue 2, 2002, Pages 391-403

  Van Cott, Elizabeth M ^a   Soderberg, Britt L ^a   Laposata, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; PROTEIN S; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ALGORITHM; BLOOD; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOPHILIA; BLEEDING; BLOOD CLOTTING; DIAGNOSTIC TEST; HOMEOSTASIS; HYPERCOAGULABILITY; PRIORITY JOURNAL; THROMBOSIS;

ALGORITHMS; HUMANS; PATHOLOGY, CLINICAL; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN S; PROTEIN S DEFICIENCY; THROMBOPHILIA; HUMAN;

EID: 0035990288     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(01)00011-7     Document Type: Review

References (32)

1. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. Protein S deficiency
4. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism
5. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
6. Anticoagulant protein C pathway defective in majority of thrombophilic patients
7. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S
8. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
9. Resistance to activated protein C as a basis for venous thrombosis
10. Activated protein C resistance assay performance: Improvement by sample dilution with factor V-deficient plasma
11. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V Leiden (FVR506Q)
12. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden
13. Modified test for activated protein C resistance
14. Resistance to activated protein C (APCR): Reference values of APC-ratios for children
15. APC resistance in neonates and infants: Adjustment of the APTT-based method
16. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction
17. A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescent resonance energy transfer (FRET) assay
18. Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay
19. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes
20. Factor V Cambridge: A new mutation (Arg306 → Thr) associated with resistance to activated protein C
21. A novel mutation of the Arg 306 of factor V gene in Hong Kong Chinese
22. Factor V Arg 306 → Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese
23. Factor V HR2: An ancient haplotype out of Africa - Reasons for being interested
24. Development of the human coagulation system in the full-term infant
25. Maturation of the hemostatic system during childhood
26. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception
27. Protein C deficiency: From gene defects to disease
28. Protein S deficiency: A data base of mutations - Summary of the first update
29. Plasma levels of protein S, protein C and factor X: Effects of sex, hormonal state and age
30. Influence of the nt 2148 A to G substitution (Pro 626 dimorphism) in the PROSI gene on circulation free protein S levels in healthy volunteers: Reappraisal of protein S normal ranges
31. How to work up hypercoagulability
32. Laboratory evaluation of hypercoagulable states